- AZN Ticker
- 🇬🇧 LSE, 🇺🇸 NYSE Exchange
- 64,400 Employees
- 💊 Health Care Sector
- 👩🏻⚕ Pharmaceuticals Industry
- Pascal Soriot CEO
9 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
Financial statements — AstraZeneca
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
27B | 24B | 22B | 22B | 23B |
| Cost Of Revenue |
|
5.3B | 4.9B | 4.9B | 4.3B | 4.1B |
| Gross Profit |
|
21B | 19B | 17B | 18B | 19B |
| Research and Development |
|
6B | 6.1B | 5.9B | 5.8B | 5.9B |
| Selling General and Admin |
|
12B | 12B | 10B | 11B | 9.7B |
| Operating Expense |
|
23B | 23B | 21B | 21B | 20B |
| Operating Income |
|
3.6B | 1.4B | 860M | 1.8B | 3.2B |
| Other Income Expense Net |
|
150M | 150M | 96M | 130M | 410M |
| EBIT |
|
3.8B | 1.4B | 840M | 1.9B | 3.5B |
| Interest Income |
|
740M | 1.3B | 760M | 680M | 680M |
| Pretax Income |
|
3.9B | 1.5B | 2B | 2.2B | 3.6B |
| Income Tax |
|
770M | 320M | -57M | -640M | 150M |
| Minority Interest |
|
-52M | -110M | 0 | -130M | 0 |
| Net Income |
|
3.2B | 1.3B | 2.1B | 3B | 3.4B |
| Net Income Basic |
|
3.2B | 1.3B | 2.1B | 3B | 3.4B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Current cash |
|
8B | 6.2B | 5.7B | 4.6B | 5.9B |
| Short term investments |
|
140M | 36M | 260M | 28M | 27M |
| Receivables |
|
7.4B | 6B | 5.8B | 5.5B | 5B |
| Inventory |
|
4B | 3.2B | 2.9B | 3B | 2.3B |
| Other current assets |
|
140M | 36M | 260M | 28M | 27M |
| Current assets |
|
20B | 16B | 16B | 13B | 13B |
| Long term investments |
|
47B | 46B | 45B | 50B | 49B |
| Property plant equipment |
|
8.3B | 7.7B | 7.4B | 7.6B | 6.8B |
| Goodwill |
|
12B | 12B | 12B | 12B | 12B |
| Intangible assets |
|
21B | 21B | 22B | 26B | 28B |
| Other assets |
|
1.6B | 1.4B | 670M | 1.4B | 1.2B |
| Total assets |
|
67B | 61B | 61B | 63B | 63B |
| Accounts payable |
|
16B | 14B | 13B | 12B | 10B |
| Current long term debt |
|
2.4B | 2B | 1.8B | 2.2B | 2.3B |
| Other current liabilities |
|
2.1B | 2.1B | 1.7B | 2.5B | 2.5B |
| Total current liabilities |
|
20B | 18B | 16B | 16B | 15B |
| Long term debt |
|
18B | 16B | 17B | 16B | 15B |
| Other liabilities |
|
9.9B | 10B | 9.7B | 11B | 12B |
| Minority Interest |
|
16M | 1.5B | 1.6B | 1.7B | 1.8B |
| Total Liabilities |
|
51B | 48B | 48B | 48B | 48B |
| Common stock |
|
2.6B | 2.6B | 2.5B | 2.5B | 2.5B |
| Retained earning |
|
5.3B | 2.8B | 5.7B | 8.2B | 8.1B |
| Treasury stock |
|
0 | 0 | 0 | 0 | 0 |
| Capital surplus |
|
• | • | • | • | • |
| Shareholder equity |
|
16B | 13B | 12B | 15B | 15B |
| Net tangible assets |
|
-17B | -19B | -21B | -23B | -24B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Net Income |
|
3.2B | 1.3B | 2.1B | 3B | 3.4B |
| Depreciation |
|
3.1B | 3.8B | 0 | 0 | 0 |
| Changes in receivables |
|
1.3B | 270M | 250M | 530M | -2B |
| Changes in inventories |
|
830M | 300M | -150M | 700M | 190M |
| Cash change |
|
1.8B | 540M | 1.1B | -1.3B | -950M |
| Cash flow |
|
4.8B | 3B | 2.6B | 3.6B | 4.1B |
| Capital expenditures |
|
-2.6B | -2.5B | -1.4B | -1.7B | -1.4B |
| Investments |
|
• | • | • | • | • |
| Investing activity other |
|
• | • | • | • | • |
| Total investing cash flows |
|
-290M | -660M | 960M | -2.3B | -4B |
| Dividends paid |
|
• | • | • | • | • |
| Net borrowings |
|
12B | 12B | 13B | 13B | 11B |
| Other financing cash flows |
|
• | • | • | • | • |
| Cash flow financing |
|
-2.2B | -1.8B | -2B | -2.9B | -1.3B |
| Exchange rate effect |
|
• | • | • | • | • |
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.